SV2 PET Imaging With [11C]APP311

RecruitingOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

December 1, 2017

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Schizophrenia and Other Psychotic DisordersCannabis Use DisorderHealthy
Interventions
DRUG

[11C]APP311

It has been shown that radiotracer \[11C\]APP311 (aka \[11C\]UCB-J) displays high specificity and selectivity for the synaptic vesicle protein SV2A. Since this protein is expressed ubiquitously in active synapses, this tracer has the potential to be a general purpose tool for quantitative imaging of synaptic density.

Trial Locations (1)

06519

RECRUITING

Conneticut Mental Health Center, New Haven

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Yale University

OTHER